BLRX ▼ -13.3% - BioLineRx Ltd. $BLRX BLRX - BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) BioLineRx shares fell 13.3% today despite the company announcing plans to present preclinical efficacy data for its GLIX1 candidate and details on an upcoming Phase 1/2a trial design at the European Association of Neuro-Oncology conference. The decline suggests investors may have interpreted the presentation schedule as an incremental development rather than a near-term catalyst, or reacted to broader market conditions unrelated to the announcement itself. 10-SEP-2026 07:01 AM ET